Literature DB >> 30190848

From personalized to patient-specific treatment of metastatic melanoma.

Robert O Dillman1.   

Abstract

Entities:  

Keywords:  autologous adoptive cell therapy; autologous dendritic cell therapeutic vaccines; autologous tumor cell lines; melanoma; patient-specific cancer therapy; personalized cancer therapy; tumor-associated antigens; tumor-infiltrating lymphocytes

Year:  2015        PMID： 30190848      PMCID： PMC6094690          DOI： 10.2217/mmt.15.20

Source DB:  PubMed          Journal:  Melanoma Manag        ISSN： 2045-0885


× No keyword cloud information.
  27 in total

1.  Tumor heterogeneity and personalized medicine.

Authors:  Dan L Longo
Journal:  N Engl J Med       Date:  2012-03-08       Impact factor: 91.245

2.  Growth of tumor-infiltrating lymphocytes from human solid cancers: summary of a 5-year experience.

Authors:  J R Yannelli; C Hyatt; S McConnell; K Hines; L Jacknin; L Parker; M Sanders; S A Rosenberg
Journal:  Int J Cancer       Date:  1996-02-08       Impact factor: 7.396

Review 3.  Cancer immunotherapy.

Authors:  Robert O Dillman
Journal:  Cancer Biother Radiopharm       Date:  2011-02       Impact factor: 3.099

4.  Tumor infiltrating lymphocyte therapy for metastatic melanoma: analysis of tumors resected for TIL.

Authors:  Stephanie L Goff; Franz O Smith; Jacob A Klapper; Richard Sherry; John R Wunderlich; Seth M Steinberg; Donald White; Steven A Rosenberg; Mark E Dudley; James C Yang
Journal:  J Immunother       Date:  2010-10       Impact factor: 4.456

5.  Phase II trial of dendritic cells loaded with antigens from self-renewing, proliferating autologous tumor cells as patient-specific antitumor vaccines in patients with metastatic melanoma: final report.

Authors:  Robert O Dillman; Senthamil R Selvan; Patric M Schiltz; Edward F McClay; Neil M Barth; Carol DePriest; Cristina de Leon; Cheryl Mayorga; Andrew N Cornforth; Kanoe Allen
Journal:  Cancer Biother Radiopharm       Date:  2009-06       Impact factor: 3.099

6.  Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.

Authors:  Caroline Robert; Antoni Ribas; Jedd D Wolchok; F Stephen Hodi; Omid Hamid; Richard Kefford; Jeffrey S Weber; Anthony M Joshua; Wen-Jen Hwu; Tara C Gangadhar; Amita Patnaik; Roxana Dronca; Hassane Zarour; Richard W Joseph; Peter Boasberg; Bartosz Chmielowski; Christine Mateus; Michael A Postow; Kevin Gergich; Jeroen Elassaiss-Schaap; Xiaoyun Nicole Li; Robert Iannone; Scot W Ebbinghaus; S Peter Kang; Adil Daud
Journal:  Lancet       Date:  2014-07-15       Impact factor: 79.321

7.  Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study.

Authors:  Antoni Ribas; Rene Gonzalez; Anna Pavlick; Omid Hamid; Thomas F Gajewski; Adil Daud; Lawrence Flaherty; Theodore Logan; Bartosz Chmielowski; Karl Lewis; Damien Kee; Peter Boasberg; Ming Yin; Iris Chan; Luna Musib; Nicholas Choong; Igor Puzanov; Grant A McArthur
Journal:  Lancet Oncol       Date:  2014-07-15       Impact factor: 41.316

8.  Dendritic Versus Tumor Cell Presentation of Autologous Tumor Antigens for Active Specific Immunotherapy in Metastatic Melanoma: Impact on Long-Term Survival by Extent of Disease at the Time of Treatment.

Authors:  Robert O Dillman; Edward F McClay; Neil M Barth; Thomas T Amatruda; Lee S Schwartzberg; Khosrow Mahdavi; Cristina de Leon; Robin E Ellis; Carol DePriest
Journal:  Cancer Biother Radiopharm       Date:  2015-06       Impact factor: 3.099

9.  Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions.

Authors:  Yong-Chen Lu; Xin Yao; Jessica S Crystal; Yong F Li; Mona El-Gamil; Colin Gross; Lindy Davis; Mark E Dudley; James C Yang; Yardena Samuels; Steven A Rosenberg; Paul F Robbins
Journal:  Clin Cancer Res       Date:  2014-07-01       Impact factor: 12.531

10.  The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment.

Authors:  Paolo A Ascierto; Mariaelena Capone; Walter J Urba; Carlo B Bifulco; Gerardo Botti; Alessandro Lugli; Francesco M Marincola; Gennaro Ciliberto; Jérôme Galon; Bernard A Fox
Journal:  J Transl Med       Date:  2013-03-03       Impact factor: 5.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.